Guest Editorial ODAC Confidential: The seven deadly sins sponsors commit again and again at FDA presentations January 20, 2023Vol.49 No.03By Mikkael A. Sekeres
Drugs & Targets Tukysa + trastuzumab receives FDA accelerated approval for previously treated metastatic CRC January 20, 2023Vol.49 No.03
Drugs & Targets FDA publishes draft guidance on optimizing dosage for oncology drugs January 20, 2023Vol.49 No.03
Drugs & Targets FDA grants accelerated approval to Lunsumio for R/R follicular lymphoma January 06, 2023Vol.49 No.01
Drugs & Targets FDA approves first gene therapy for high-risk, non-muscle-invasive bladder cancer January 06, 2023Vol.49 No.01
Drugs & Targets FDA approves imaging drug to help identify lung cancer lesions January 06, 2023Vol.49 No.01
Drugs & Targets FDA accepts supplemental BLAs for Padcev + Keytruda for urothelial cancer January 06, 2023Vol.49 No.01
Drugs & Targets Panel submits operational evaluation of FDA’s tobacco program January 06, 2023Vol.49 No.01
